Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8530742 | 0.84 | SRC (0.58) | SRCL3MBTL1TDP1KDM4EHPGD | |
| SCHEMBL1009459 | 0.84 | SRC (0.58) | SRCL3MBTL1TDP1KDM4EHPGD | |
| SCHEMBL29767782 | 0.81 | SRC (0.45) | SRCL3MBTL1TDP1KDM4EHPGD | |
| SCHEMBL28781038 | 0.80 | SRC (0.67) | SRCL3MBTL1TDP1KDM4EHPGD | |
| SCHEMBL29227303 | 0.80 | HPGD (0.55) | SRCL3MBTL1TDP1KDM4EHPGD | |
| SCHEMBL19348680 | 0.80 | SRC (0.54) | SRCL3MBTL1TDP1KDM4EHPGD | |
| SCHEMBL1011207 | 0.80 | SRC (0.54) | SRCL3MBTL1TDP1KDM4EHPGD | |
| SCHEMBL19348760 | 0.80 | SRC (0.54) | SRCL3MBTL1TDP1KDM4EHPGD | |
| SCHEMBL29044095 | 0.79 | SRC (0.52) | SRCL3MBTL1TDP1KDM4EHPGD | |
| Lithium Ion SCHEMBL31460437 | 0.78 | SRC (0.52) | SRCL3MBTL1TDP1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2535975-B1 | NONAQUEOUS ELECTROLYTE SOLUTION, AND LITHIUM ION SECONDARY BATTERY USING SAME | ENVISION AESC ENERGY DEVICES LTD (JP) | 2020-01-08 | — | — | EP | claimed |
| EP-2768837-B1 | NOVEL TETRAOXASPIRO[5.5]UNDECANE BASED PHOSPHATE COMPOUNDS AND THEIR USE AS FLAME RETARDANTS | PERSTORP AB (SE) | 2016-12-07 | — | — | EP | claimed |
| CN-115385953-B | Diphenylphosphono fluorine-containing imide compound, and preparation method and application thereof | 北京理工大学 | 2025-07-11 | — | — | CN | disclosed |
| CN-115385953-B | Diphenylphosphono fluorine-containing imide compound, and preparation method and application thereof | 北京理工大学 | 2025-07-11 | — | — | CN | disclosed |
| CN-118754913-A | Method for converting bisaryl phosphine oxide by using sulfur hexafluoride | 国网安徽省电力有限公司电力科学研究院 | 2024-10-11 | — | — | CN | disclosed |
| CN-116804029-B | Fluorination method of secondary phosphine oxide | 浙江工业大学 | 2024-08-27 | — | — | CN | disclosed |
| CN-116804029-A | Fluorination method of secondary phosphine oxide | 浙江工业大学 | 2023-09-26 | — | — | CN | disclosed |
| CN-113583042-B | Preparation method of phosphoryl fluoride compound | 烟台大学 | 2023-08-29 | — | — | CN | disclosed |
| CN-115385953-A | Diphenylphosphono fluorine-containing imide compound and preparation method and application thereof | 北京理工大学 | 2022-11-25 | — | — | CN | disclosed |
| CN-115385953-A | Diphenylphosphono fluorine-containing imide compound and preparation method and application thereof | 北京理工大学 | 2022-11-25 | — | — | CN | disclosed |
| CN-113583042-A | Preparation method of phosphoryl fluoride compound | 烟台大学 | 2021-11-02 | — | — | CN | disclosed |
| EP-1798792-A1 | NONAQUEOUS ELECTROLYTE SOLUTION, AND NONAQUEOUS ELECTROLYTE BATTERY HAVING SAME | Bridgestone Corporation (JP) | 2007-06-20 | — | — | EP | disclosed |
| US-20040121405-A1 | Selective covalent-binding compounds having therapeutic diagnostic and analytical applications | SEMOREX INC. | 2004-06-24 | — | — | US | disclosed |
| EP-1385988-A2 | SELECTIVE COVALENT-BINDING COMPOUNDS HAVING THERAPEUTIC DIAGNOSTIC AND ANALYTICAL APPLICATIONS | Semorex Inc. (US) | 2004-02-04 | — | — | EP | disclosed |
| WO-2002083708-A2 | SELECTIVE COVALENT-BINDING COMPOUNDS HAVING THERAPEUTIC DIAGNOSTIC AND ANALYTICAL APPLICATIONS | SEMOREX INC. (US) | 2002-10-24 | — | — | WO | disclosed |
| US-5484890-A | FACTOR VIII WITH STABILIZERS | JOHNSON ALAN J (US) | 1996-01-16 | — | — | US | disclosed |
| EP-0651770-A1 | ANTIHEMOPHILIC FACTOR STABILIZATION | JOHNSON, Alan J. (US) | 1995-05-10 | — | — | EP | disclosed |
| EP-0651770-A4 | ANTIHEMOPHILIC FACTOR STABILIZATION. | JOHNSON ALAN J (US) | 1995-03-23 | — | — | EP | disclosed |
| US-5278289-A | Purification by ionic exchanging | JOHNSON ALAN J (US) | 1994-01-11 | — | — | US | disclosed |
| WO-1993010143-A1 | ANTIHEMOPHILIC FACTOR STABILIZATION | JOHNSON ALAN J (US) | 1993-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040121405-A1 | Selective covalent-binding compounds having therapeutic diagnostic and analytical applications | CD2BP2, HAVCR2, EPCAM | SRC 760/4885L3MBTL1 771/4885TDP1 2931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.